关注的SARS-CoV-2突变体刺突蛋白显著突变的鉴定和有效抑制剂的发现

IF 1.1 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Global Health Epidemiology and Genomics Pub Date : 2025-04-28 eCollection Date: 2025-01-01 DOI:10.1155/ghe3/5042190
Mohsen Almakrami, Mohammed Bazuqamah, Mohammed A Alshehri, Abdulaziz M S Alqahtani, Sultan F Kadasah, Naif Harthi, Rami Ali Alyami, Abdulmajeed Alqurashi, Abdulhadi A Al Ruwaithi
{"title":"关注的SARS-CoV-2突变体刺突蛋白显著突变的鉴定和有效抑制剂的发现","authors":"Mohsen Almakrami, Mohammed Bazuqamah, Mohammed A Alshehri, Abdulaziz M S Alqahtani, Sultan F Kadasah, Naif Harthi, Rami Ali Alyami, Abdulmajeed Alqurashi, Abdulhadi A Al Ruwaithi","doi":"10.1155/ghe3/5042190","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> SARS-CoV-2 is a positive-sense single-stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. <b>Aim:</b> This research aimed at studying significant mutations in spike protein of SARS-CoV-2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS-CoV-2 spike protein and its latest omicron VoC. <b>Methodology:</b> In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS-CoV-2. Subsequently, we determined the structure of the wild-type SARS-CoV-2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS-CoV-2 omicron variant was modeled in SWISS-MODEL. The ligand dataset for spike protein of SARS-CoV-2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. <b>Results:</b> AZ_2 demonstrated a docking score of -6.1753 in MOE, with energy values of -4.3889 and -6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of -5.9, with energy values of -9.3 and -5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target-based drug against SARS-CoV-2 and its omicron variant. <b>Outcomes:</b> Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS-CoV-2 and its omicron variant.</p>","PeriodicalId":44052,"journal":{"name":"Global Health Epidemiology and Genomics","volume":"2025 ","pages":"5042190"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052452/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification of Significant Mutations in Spike Protein of SARS-CoV-2 Variants of Concern and the Discovery of Potent Inhibitors.\",\"authors\":\"Mohsen Almakrami, Mohammed Bazuqamah, Mohammed A Alshehri, Abdulaziz M S Alqahtani, Sultan F Kadasah, Naif Harthi, Rami Ali Alyami, Abdulmajeed Alqurashi, Abdulhadi A Al Ruwaithi\",\"doi\":\"10.1155/ghe3/5042190\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> SARS-CoV-2 is a positive-sense single-stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. <b>Aim:</b> This research aimed at studying significant mutations in spike protein of SARS-CoV-2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS-CoV-2 spike protein and its latest omicron VoC. <b>Methodology:</b> In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS-CoV-2. Subsequently, we determined the structure of the wild-type SARS-CoV-2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS-CoV-2 omicron variant was modeled in SWISS-MODEL. The ligand dataset for spike protein of SARS-CoV-2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. <b>Results:</b> AZ_2 demonstrated a docking score of -6.1753 in MOE, with energy values of -4.3889 and -6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of -5.9, with energy values of -9.3 and -5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target-based drug against SARS-CoV-2 and its omicron variant. <b>Outcomes:</b> Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS-CoV-2 and its omicron variant.</p>\",\"PeriodicalId\":44052,\"journal\":{\"name\":\"Global Health Epidemiology and Genomics\",\"volume\":\"2025 \",\"pages\":\"5042190\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052452/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Health Epidemiology and Genomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/ghe3/5042190\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Health Epidemiology and Genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ghe3/5042190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:SARS-CoV-2是一种正感单链RNA病毒,具有感染上皮细胞和呼吸系统的倾向。两种重要的蛋白质,结构蛋白和非结构蛋白,构成了这种病毒的结构。目的:本研究旨在研究SARS-CoV-2关注变异体(VoCs)刺突蛋白的显著突变,并寻找组粒与其他四种变异体(α、β、γ和δ)之间的共同突变。本研究的目的是对野生型和突变型蛋白进行结构比较,然后确定可用于对抗SARS-CoV-2刺突蛋白及其最新组粒VoC的有效抑制剂(配体)。方法:在本研究中,我们研究了SARS-CoV-2刺突区存在的16个主要突变和共有突变(6个)。随后,我们从蛋白质数据库(PDB)中确定了野生型SARS-CoV-2蛋白的结构,其ID为7R4I。此外,在SWISS-MODEL中建立了SARS-CoV-2组粒变体突变蛋白的结构模型。从文献和不同数据库中收集SARS-CoV-2刺突蛋白配体数据集。野生型和突变型蛋白在分子操作环境(MOE)中与配体数据库对接。通过对接分析,根据能量值、相互作用和对接分数确定了两个最佳配体分子AZ_2和AZ_13,并将其用于野生蛋白和突变蛋白的对接。结果:AZ_2的MOE对接评分为-6.1753,能量值分别为-4.3889和-6.1753。形成了关键的氢键相互作用。AZ_13的对接分数为-5.9,能量值分别为-9.3和-5.9,与Asp950 (3.06 Å)、Ile312 (3.13 Å)和Glu309 (3.27 Å)形成氢供体和受体相互作用。这些相互作用显示出很强的结合亲和力和潜在的功效。因此,目前的研究工作重点是鉴定重大突变,并寻找一种有效的靶向药物来对抗SARS-CoV-2及其组粒变体。结果:基于所进行的计算分析,建议所提出的化合物可用于治疗SARS-CoV-2及其组粒变体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of Significant Mutations in Spike Protein of SARS-CoV-2 Variants of Concern and the Discovery of Potent Inhibitors.

Background: SARS-CoV-2 is a positive-sense single-stranded RNA virus that has a propensity for infecting epithelial cells and the respiratory system. The two important proteins, structural and nonstructural proteins, make the architecture of this virus. Aim: This research aimed at studying significant mutations in spike protein of SARS-CoV-2 variants of concern (VoCs) and finding shared mutations among omicron and other four variants (alpha, beta, gamma, and delta). The purpose of this study was to draw structural comparisons between wild type and mutant proteins, followed by identifying potent inhibitors (ligand) that could be used against SARS-CoV-2 spike protein and its latest omicron VoC. Methodology: In this research, we had studied 16 major mutations as well as shared mutations (6) present in spike region of SARS-CoV-2. Subsequently, we determined the structure of the wild-type SARS-CoV-2 protein from the Protein Data Bank (PDB) with the ID 7R4I. Furthermore, the structure of the mutant protein of SARS-CoV-2 omicron variant was modeled in SWISS-MODEL. The ligand dataset for spike protein of SARS-CoV-2 was also collected from literature and different databases. Both wild type and mutant proteins were docked with ligand database in Molecular Operating Environment (MOE). The docking analysis was performed, and two best ligand molecules, AZ_2 and AZ_13, were finalized based on their energy values, interactions, and docking scores to be used against our wild and mutant proteins. Results: AZ_2 demonstrated a docking score of -6.1753 in MOE, with energy values of -4.3889 and -6.1753. It formed key hydrogen bond interactions. AZ_13 showed a docking score of -5.9, with energy values of -9.3 and -5.9, forming hydrogen donor and acceptor interactions with Asp950 (3.06 Å), Ile312 (3.13 Å), and Glu309 (3.27 Å). These interactions suggest strong binding affinity and potential efficacy. Thus, present research work emphasized on identification of significant mutations and finding a potent target-based drug against SARS-CoV-2 and its omicron variant. Outcomes: Based on this computational analysis performed, it is suggested that proposed compound can be used as remedy against SARS-CoV-2 and its omicron variant.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Global Health Epidemiology and Genomics
Global Health Epidemiology and Genomics PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
1.40
自引率
0.00%
发文量
10
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信